99 results
8-K
ELOX
Eloxx Pharmaceuticals, Inc.
1 Aug 08
Other Events
12:00am
. (the “Company”) announced that Bayer CropScience has successfully completed the first R&D milestone related to Bayer’s use of Senesco’s technology … Bayer.
On August 1, 2008, the Company issued a press release announcing the completion of the first R&D milestone related to Bayer’s use of Senesco’s
8-K
EX-99.1
ELOX
Eloxx Pharmaceuticals, Inc.
7 May 21
Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update
12:00am
expenses (R&D) were $4.1 million for the three months ended March 31, 2021, which includes $0.2 million in stock-based compensation. For the same … period in the prior year, R&D expenses were $4.8 million. The decrease in R&D expenses was driven by reduced expenses related to the development of ELX-02
8-K
EX-99.1
ELOX
Eloxx Pharmaceuticals, Inc.
11 Mar 21
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business Update
4:25pm
&D expenses were $5.9 million. The quarter-to-quarter decrease in R&D expenses of $3.3 million was driven by reduced headcount and related salaries … . For the same period in the prior year, R&D expenses were $26.3 million. The year over year decrease in R&D expenses of $11.7 million was driven by reduced
8-K
EX-99.1
ELOX
Eloxx Pharmaceuticals, Inc.
7 Aug 19
Eloxx Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results and Provides Business Update
8:00am
June 30, 2019 which includes $2.3 million non-cash expense related to stock-based compensation. For the same period in the prior year, R&D expenses … were $4.2 million. Quarter over quarter increases in R&D expenditures were driven by our Phase 1 clinical studies, the renal impairment study
8-K
EX-99.1
ELOX
Eloxx Pharmaceuticals, Inc.
5 Nov 19
Eloxx Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results and Provides Business Update
4:12pm
compensation. For the same period in the prior year, R&D expenses were $5.4 million. Quarter to quarter increases in R&D expenditures were largely driven … , R&D expenses were $14.0 million. The year over year increase in R&D expenditures was driven primarily by growth in our clinical and preclinical
8-K
xhs9spc
5 Dec 08
Termination of a Material Definitive Agreement
12:00am
8-K
EX-99.1
9zv muk2yl8hviz
6 Aug 20
Eloxx Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results and Provides Business Update
8:15am
8-K
EX-99.1
orxja32wivl
5 Mar 20
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial and Operating Results and Provides Business Update
4:13pm
8-K
EX-99.1
putags
1 Aug 08
Other Events
12:00am
8-K
EX-99.1
iep9ado
15 Aug 22
Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update
4:18pm
8-K
EX-99.1
lml2u8bqd5
5 Nov 20
Eloxx Pharmaceuticals Reports Third Quarter 2020 Financial and Operating Results and Provides Business Update
4:26pm
8-K
EX-99.1
edbn ihks5rt7jp7xx
17 Aug 21
Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update
12:00am
8-K
EX-99.1
rs9 ow4iaezr69
3 Apr 23
Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update
9:27am
8-K
EX-99.1
1uwy8cov
15 May 23
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
6:01pm
8-K
EX-99.1
14xn05 5jifr
14 Aug 23
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
11:56am
8-K
EX-99.1
1vimhaif1ay snj
9 Nov 21
Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update
8:03am
8-K
EX-99.1
gxsd1lpscu
14 Nov 22
Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update
4:09pm
8-K
EX-99.1
5jlncrt1fo7vyn30s
1 Dec 11
Senesco Receives Milestone Payment from Bayer CropScience
12:00am
8-K
EX-99.1
fkwjv33pougx6ar
10 May 22
Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update
5:28pm
8-K
EX-99.1
pfchyxll6rz
13 Nov 23
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
4:58pm